Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Davis

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Clinical Pharmacology and Therapeutics|December 14, 2023
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical DevelopmentJohn D Davis, Marçal Bravo Padros, Daniela J Conrado, et al.
The AAPS Journal|October 23, 2025
Association of Immunogenicity and Drug Exposure and the Importance of Target Engagement in ADA Development: A Clinical Case Study of Anti-SARS-CoV-2 BiotherapeuticsSusan C Irvin, Samit Ganguly, Zhiqiang Wang, et al.
JAMA Dermatology|December 27, 2019
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical TrialMargitta Worm, Eric L Simpson, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|June 24, 2020
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S Paller, Elaine C Siegfried, Diamant Thaçi, et al.
Frontiers in Immunology|November 26, 2024
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitisMohamed A Kamal, Matthew P Kosloski, Ching-Ha Lai, et al.
BMJ Open|October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 studyThomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Journal of the Pediatric Infectious Diseases Society|October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Journal of the American Academy of Dermatology|August 3, 2019
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyMette Deleuran, Diamant Thaçi, Lisa A Beck, et al.
JAMA Dermatology|November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical TrialEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
JAMA Network Open|August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialCynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Clinical Pharmacology and Therapeutics|December 14, 2023
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical DevelopmentJohn D Davis, Marçal Bravo Padros, Daniela J Conrado, et al.
The AAPS Journal|October 23, 2025
Association of Immunogenicity and Drug Exposure and the Importance of Target Engagement in ADA Development: A Clinical Case Study of Anti-SARS-CoV-2 BiotherapeuticsSusan C Irvin, Samit Ganguly, Zhiqiang Wang, et al.
JAMA Dermatology|December 27, 2019
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical TrialMargitta Worm, Eric L Simpson, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|June 24, 2020
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S Paller, Elaine C Siegfried, Diamant Thaçi, et al.
Frontiers in Immunology|November 26, 2024
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitisMohamed A Kamal, Matthew P Kosloski, Ching-Ha Lai, et al.
BMJ Open|October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 studyThomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Journal of the Pediatric Infectious Diseases Society|October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Journal of the American Academy of Dermatology|August 3, 2019
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyMette Deleuran, Diamant Thaçi, Lisa A Beck, et al.
JAMA Dermatology|November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical TrialEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
JAMA Network Open|August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialCynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Pageof 9